![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SORCS1 |
Gene summary for SORCS1 |
![]() |
Gene information | Species | Human | Gene symbol | SORCS1 | Gene ID | 114815 |
Gene name | sortilin related VPS10 domain containing receptor 1 | |
Gene Alias | hSorCS | |
Cytomap | 10q25.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B3KVZ0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114815 | SORCS1 | S014 | Human | Liver | HCC | 6.02e-18 | 7.52e-01 | 0.2254 |
114815 | SORCS1 | S015 | Human | Liver | HCC | 3.17e-08 | 3.87e-01 | 0.2375 |
114815 | SORCS1 | S016 | Human | Liver | HCC | 8.57e-24 | 8.21e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:000689221 | Liver | HCC | post-Golgi vesicle-mediated transport | 77/7958 | 104/18723 | 6.14e-11 | 2.24e-09 | 77 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SORCS1 | SNV | Missense_Mutation | novel | c.654N>T | p.Glu218Asp | p.E218D | Q8WY21 | protein_coding | tolerated(0.15) | benign(0.255) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SORCS1 | SNV | Missense_Mutation | rs772536992 | c.2524G>A | p.Ala842Thr | p.A842T | Q8WY21 | protein_coding | tolerated(0.13) | possibly_damaging(0.643) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SORCS1 | SNV | Missense_Mutation | novel | c.1109C>A | p.Ser370Tyr | p.S370Y | Q8WY21 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SORCS1 | SNV | Missense_Mutation | novel | c.455G>A | p.Arg152His | p.R152H | Q8WY21 | protein_coding | tolerated_low_confidence(0.13) | benign(0.207) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SORCS1 | SNV | Missense_Mutation | novel | c.2039C>T | p.Pro680Leu | p.P680L | Q8WY21 | protein_coding | deleterious(0.04) | benign(0.025) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SORCS1 | SNV | Missense_Mutation | rs201889963 | c.2572N>A | p.Val858Ile | p.V858I | Q8WY21 | protein_coding | tolerated(0.48) | benign(0.024) | TCGA-PG-A6IB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SORCS1 | SNV | Missense_Mutation | rs780091835 | c.460C>T | p.Arg154Trp | p.R154W | Q8WY21 | protein_coding | deleterious(0.01) | possibly_damaging(0.723) | TCGA-PG-A917-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SORCS1 | deletion | Frame_Shift_Del | c.837delN | p.His280ThrfsTer43 | p.H280Tfs*43 | Q8WY21 | protein_coding | TCGA-AP-A0LP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Hormone Therapy | megace | SD | |||
SORCS1 | insertion | In_Frame_Ins | novel | c.2797-1_2797insTTAAACAGCAGTGGCCTTGTGTGCTGGCCC | p.Glu932_Pro933insLeuAsnSerSerGlyLeuValCysTrpPro | p.E932_P933insLNSSGLVCWP | Q8WY21 | protein_coding | TCGA-B5-A11F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD | ||
SORCS1 | insertion | Nonsense_Mutation | novel | c.3083_3084insCGTCAGCCCACTGGAGTTACTCTTCAAATAG | p.Leu1028PhefsTer11 | p.L1028Ffs*11 | Q8WY21 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |